Industries > Pharma > Pharmaceutical Contract Manufacturing Market 2018-2028

Pharmaceutical Contract Manufacturing Market 2018-2028

Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

PUBLISHED: 27 June 2018
PAGES: 230
PRODUCT CODE: PHA0321
SUBMARKET: Contract Services

Clear
WOOCS 2.2.1

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The API Manufacturing submarket held 66% of the market in 2017. Visiongain estimated that the pharmaceutical contract manufacturing market will reach $93bn in 2022.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 230-page report you will receive 77 tables and 58 figures– all unavailable elsewhere.

The 230-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Pharmaceutical Contract Manufacturing Market forecasts from 2018-2028

• Submarket forecasts at world level, from 2018-2028:
Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
Other applications of outsourced production – other related services

• Revenue forecasts from 2018-2028, for these regional and national markets:
• The US
• Canada
• Japan
• EU5: Germany, France, the UK, Italy and Spain
• BRIC: Brazil, Russia, India, China
• South Korea
• Turkey
• Mexico
• Others

Pharmaceutical Contract Manufacturing Market 2018-2028

• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

• Qualitative Analysis from a CMO Perspective

• Qualitative Analysis from a Client Perspective

Visiongain’s study is intended for anyone requiring commercial analyses for the pharmaceutical contract manufacturing market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2018-2028: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2018-2028


Latest Pharma news

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

READ

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

READ

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

READ

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

READ

Categories

Category